[Preprint] Observational study in Brazil showed the J&J vaccine adjusted effectiveness was 50.9% against any symptomatic Covid-19, 72.9% for hospitalization, 92.5% for ICU admission, 88.7% for mechanical ventilation, and 90.5% for death.
Vaccine effectiveness of Ad26.COV2.S against symptomatic COVID-19 and clinical outcomes in Brazil: a test-negative study design – medRxiv
The post [Preprint] Observational study in Brazil showed the J&J vaccine adjusted effectiveness was 50.9% against any symptomatic Covid-19, 72.9% for hospitalization, 92.5% for ICU admission, 88.7% for mechanical ventilation, and 90.5% for death. appeared first on Links Medicus.
Should You Mix and Match Your Booster Shot?
Should You Mix and Match Your Booster Shot? – The Atlantic Related: Study evaluated several heterologous SARS-CoV-2 vaccine regimens; no efficacy data but there was increased antibody production on study days 15 and 29 after booster shots from Moderna and Pfizer. A primer on what we know about mixing and matching Covid vaccines. Real-world data […]
The post Should You Mix and Match Your Booster Shot? appeared first on Links Medicus.
Cohort Study: The effectiveness of heterologous AstraZeneca (AZ)/mRNA prime-boost vaccination was more significant (68%) compared to the effectiveness of homologous AZ/AZ vaccination (50%) against symptomatic Covid-19 infection in Sweden.
Effectiveness of heterologous ChAdOx1 nCoV-19 and mRNA prime-boost vaccination against symptomatic Covid-19 infection in Sweden: A nationwide cohort study – The Lancet Regional Health Europe Commentary: High effectiveness of mix-and-match COVID-19 vaccines – UMEA University Related: Study evaluated several heterologous SARS-CoV-2 vaccine regimens; no efficacy data but there was increased antibody production on study days […]
The post Cohort Study: The effectiveness of heterologous AstraZeneca (AZ)/mRNA prime-boost vaccination was more significant (68%) compared to the effectiveness of homologous AZ/AZ vaccination (50%) against symptomatic Covid-19 infection in Sweden. appeared first on Links Medicus.
RCT: Interferon does not improve outcomes for hospitalized adults with COVID-19.
News release: Interferon does not improve outcomes for hospitalized adults with COVID-19 – NIH News Releases Original study: Efficacy of interferon beta-1a plus remdesivir compared with remdesivir alone in hospitalised adults with COVID-19: a double-bind, randomised, placebo-controlled, phase 3 trial – The Lancet Respiratory Medicine
The post RCT: Interferon does not improve outcomes for hospitalized adults with COVID-19. appeared first on Links Medicus.
Long-term consequences of the misuse of ivermectin data.
Long-term consequences of the misuse of ivermectin data – The Lancet Infectious Diseases Related: Ivermectin: How false science created a Covid ‘miracle’ drug. Fraudulent ivermectin studies open up new battleground between science and misinformation. The lesson of ivermectin: meta-analyses based on summary data alone are inherently unreliable. Ivermectin: Cochrane’s most talked about review so far, […]
The post Long-term consequences of the misuse of ivermectin data. appeared first on Links Medicus.
Systematic Review: Colchicine for the treatment of COVID‐19 – not beneficial for hospitalized patients; inconclusive evidence for the treatment of non-hospitalized patients, “probably slightly reduces the need for hospitalization or death within 28 days c
Colchicine for the treatment of COVID‐19 – Cochrane Library Related: [Preprint] PRINCIPLE RCT: Colchicine does not improve time to recovery in outpatients with Covid-19 at higher risk of complications. COLCORONA RCT: Colchicine for community-treated patients with COVID-19 – findings suggest it may lower death and hospital admission rates, but further studies are required. [Preprint] RECOVERY […]
The post Systematic Review: Colchicine for the treatment of COVID‐19 – not beneficial for hospitalized patients; inconclusive evidence for the treatment of non-hospitalized patients, “probably slightly reduces the need for hospitalization or death within 28 days compared to placebo”. appeared first on Links Medicus.
RECOVERY Trial: In patients admitted to hospital with COVID-19, Colchicine did not reduce 28-day mortality, duration of hospital stay, or risk of progressing to invasive mechanical ventilation or death.
Colchicine in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial – The Lancet Respiratory Medicine Related: [Preprint] PRINCIPLE RCT: Colchicine does not improve time to recovery in outpatients with Covid-19 at higher risk of complications. COLCORONA RCT: Colchicine for community-treated patients with COVID-19 – findings suggest it may lower death […]
The post RECOVERY Trial: In patients admitted to hospital with COVID-19, Colchicine did not reduce 28-day mortality, duration of hospital stay, or risk of progressing to invasive mechanical ventilation or death. appeared first on Links Medicus.
What can masks do? Part 2: What makes for a good mask study — and why most fail.
COMMENTARY: What can masks do? Part 2: What makes for a good mask study — and why most fail – CIDRAP See also: COMMENTARY: What can masks do? Part 1: The science behind COVID-19 protection – CIDRAP
The post What can masks do? Part 2: What makes for a good mask study — and why most fail. appeared first on Links Medicus.
[Preprint] Breakthrough SARS-CoV-2 infections in 620,000 U.S. Veterans, February 1, 2021 to August 13, 2021 – “Vaccine protection declined by mid-August 2021, decreasing from 91.9% in March to 53.9%”.
Breakthrough SARS-CoV-2 infections in 620,000 U.S. Veterans, February 1, 2021 to August 13, 2021 – medRxiv Related: Observational study in Qatar showed the effectiveness of Pfizer vaccine against any SARS-CoV-2 infection dropped to 20% in months 5 through 7 after the second dose, but effectiveness against severe Covid-19 remained high. Cohort study: Pfizer vaccine effectiveness […]
The post [Preprint] Breakthrough SARS-CoV-2 infections in 620,000 U.S. Veterans, February 1, 2021 to August 13, 2021 – “Vaccine protection declined by mid-August 2021, decreasing from 91.9% in March to 53.9%”. appeared first on Links Medicus.
J&J COVID-19 Vaccine: FDA recommends booster shot for all adults aged 18 and older at least two months following initial vaccination with the single-shot vaccine.
News release: Johnson & Johnson COVID-19 Vaccine Booster Shot Unanimously Recommended for Emergency Use Authorization by U.S. FDA Advisory Committee Commentaries: FDA panel endorses booster shot for J&J COVID-19 vaccine – Associated Press The Johnson & Johnson one-dose vaccine offers good protection now. A booster shot will maximize that, experts say – CNN FDA advisers […]
The post J&J COVID-19 Vaccine: FDA recommends booster shot for all adults aged 18 and older at least two months following initial vaccination with the single-shot vaccine. appeared first on Links Medicus.